Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
+14.3%		$0.00
$0.00
▼
$0.39
$33K-9.0262,101 shs1,038 shs
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
$0.97
$0.37
▼
$1.67
$21K-0.39525,982 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.193,488 shs500 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.02
+7,400.0%		$0.01
$0.00
▼
$0.07
$79K1.414,973 shs365 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
+14.29%-11.11%-68.00%-86.89%-99.80%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
0.00%0.00%0.00%0.00%+150.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%0.00%+33.33%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%+14.50%+18.11%+14.50%-59.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
+14.3%		$0.00
$0.00
▼
$0.39
$33K-9.0262,101 shs1,038 shs
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
$0.97
$0.37
▼
$1.67
$21K-0.39525,982 shsN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.193,488 shs500 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.02
+7,400.0%		$0.01
$0.00
▼
$0.07
$79K1.414,973 shs365 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
+14.29%-11.11%-68.00%-86.89%-99.80%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
0.00%0.00%0.00%0.00%+150.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%0.00%+33.33%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%+14.50%+18.11%+14.50%-59.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/AN/AN/AN/A($0.27) per shareN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/AN/AN/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%11/10/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
N/A
0.35
0.35
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
5.88%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
7.90%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Innovate Biopharmaceuticals Inc stock logo
INNT
Innovate Biopharmaceuticals
841.33 millionN/ANot Optionable
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
942.08 million39.94 millionNot Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs
April 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/antibody-drug-conjugates-adc-market-095100337.html
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
January 18, 2026  |  defenseworld.netD
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...
July 16, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2982429/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting--urges-stockholders-to-vote-for-approval-of-dissolution-proposal--vinc-stock-news
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116827/0/en/Vincerx-Pharma-Inc-Announces-Additional-Adjournment-of-Special-Meeting-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal.html
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times
July 9, 2025  |  manilatimes.netM
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar
July 9, 2025  |  morningstar.comM
Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance
July 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VINC/financials/
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111291/0/en/Vincerx-Pharma-Inc-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal-and-Announces-Potential-Range-for-Distributions-to-Stockholders.html
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
July 2, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VINC/press-releases/
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
June 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/18/3101905/0/en/Vincerx-Pharma-Inc-Announces-Adjournment-of-Special-Meeting-Will-Reconvene-Meeting-on-July-16-2025-to-Secure-Votes-Needed-to-Approve-Dissolution-Proposal.html
Vincerx Pharma announces plan to delist from Nasdaq
April 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-plan-to-delist-from-nasdaq-1034597516
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vincerx-pharma-inc-announces-intent-204500865.html
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/17/3063864/0/en/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-deregister-with-the-sec.html
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down
April 9, 2025  |  fiercebiotech.comF
Vincerx terminates letter of intent with Global Digital, initiates wind down
April 9, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-terminates-letter-of-intent-with-global-digital-initiates-wind-down-1034562524
Financially struggling drugmaker's potential rescue falls apart. It now will wind down
April 9, 2025  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2025/04/08/cancer-vincerx-pharma-qumulusai-merger-fails.html
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
April 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/08/3057992/0/en/Vincerx-Pharma-Announces-Termination-of-Letter-of-Intent-and-Board-Authorization-to-Pursue-Wind-Down-Activities.html
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-non-binding-loi-for-qumulus-ai-combination-1034489795
Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
March 18, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64858522-vincerx-pharma-inc-vincerx-pharma-announces-non-binding-letter-of-intent-for-business-combination-with-qumulusai-399.htm
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis
March 18, 2025  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0008 +0.00 (+14.29%)
As of 09/10/2026 01:10 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Innovate Biopharmaceuticals stock logo

Innovate Biopharmaceuticals NASDAQ:INNT

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0004 0.00 (0.00%)
As of 09/10/2026 01:42 PM Eastern

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.02 +0.01 (+7,400.00%)
As of 09/10/2026 11:42 AM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas